Sep 23 2009
MSGI Security Solutions Inc. (OTCBB: MSGI) today reported that the Company is launching its first product derived from NASA technology, a handheld test for Diabetes, which uses breath instead of blood.
Nanobeak Inc., an MSGI subsidiary, is a nanotechnology company focused on carbon based chemical sensing for gas and organic vapor detection. Nanobeak will take the prototype handheld sensor, which measures acetone levels with a simple breath, out of the laboratory and into the marketplace. The first step involves product testing which will be done in conjunction with a major hospital network in the United States, followed by licensing discussions with the top pharmaceutical companies.
According to the International Diabetes Federation, Diabetes currently affects 246 million people worldwide and is expected to affect 380 million by 2025. At least 50% of all people with Diabetes are unaware of their condition. In some countries this figure may reach 80%. Every 10 seconds a person dies from Diabetes-related causes. India has the largest number of people with Diabetes estimated at 40.9 million. According to the American Diabetes Association, there are 23.6 million children and adults in the United States with Diabetes.
Diabetes is a disease in which the body does not produce or properly use insulin. Insulin is a hormone that is needed to convert sugar, starches and other food into energy needed for daily life. The cause of Diabetes continues to be a mystery, although both genetics and environmental factors such as obesity and lack of exercise appear to play roles. Acetone is the organic compound with the formula OC(CH3)2. This colorless liquid is the simplest example of the ketones. Ketones are the byproduct of a process called Gluconeogenesis
Jeremy Barbera, Chairman and CEO of MSGI commented; “we are excited to announce the first breakthrough in technology that has reached the prototype stage resulting from our new relationship with NASA. With nearly 250 million people in the world affected by Diabetes, we see a clear opportunity to partner with a major pharmaceutical company in licensing our first product. This device will ultimately be marketed to consumers who will be able to determine their health risks with nothing more than a simple breath. If more than 50% of all people who have Diabetes are unaware of that fact, our product will provide a seamless test to save lives by providing early detection.
Nanobeak is the first of several majority owned subsidiaries, each of which will hold the rights to a specific technology. We will be announcing the other subsidiaries and their various breakthrough technologies over the course of the next several weeks.”